Business Wire

“Look for the WELL Health-Safety Seal” Public Awareness Campaign Launches, Featuring Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17th U.S. Surgeon General Richard Carmona

25.1.2021 16:00:00 EET | Business Wire | Press release

Share

As the world continues to battle COVID-19 and communities strive to get back to business, it is more important than ever to raise confidence in the safety of buildings and shared spaces. Today, Lady Gaga, Jennifer Lopez, Michael B. Jordan, Robert DeNiro, Venus Williams, Wolfgang Puck, Deepak Chopra and 17th Surgeon General Richard Carmona came together in a new integrated ad campaign to raise awareness about the importance of the WELL Health-Safety Rating, an evidence-based third-party designation to verify that a building or space has taken the necessary steps to prioritize the health and safety of their staff, visitors and other stakeholders. The ambassadors encourage people to look for buildings and spaces with the WELL Health-Safety seal on their windows or doors to feel more confident in their decision to go inside.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005216/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

WELL Health-Safety Seal (Photo: Business Wire)

This national advertising campaign, a first from the International WELL Building Institute (IWBI), the global authority on how we can use our buildings and communities to advance the health and well-being of the people inside, explains the importance of health and safety through building design and operations as well as organizational policy, and sheds light on what the featured ambassadors have missed most during the pandemic. From Jennifer Lopez’s family movie nights to Robert DeNiro missing a “variety in existence,” each of these cultural influencers are feeling the longing for shared connection as much as the rest of us, even beyond the changes to their respective industries and day-to-day lives.

“This is more than an awareness campaign; it’s meant to ignite a movement. These ambassadors and cultural influencers are partnering with us because they truly believe in the mission – and how critical it is – to make buildings and shared spaces center on health going forward,” said Paul Scialla, Founder of the International WELL Building Institute and CEO of its parent company, Delos. “To succeed at scale means we are improving indoor spaces to help ensure that the people who visit them can be healthier and safer. This is a win for everyone involved.”

The WELL Health-Safety Rating brings together building expertise and nearly a decade of health science to promote indoor safety, creating an efficient and cost-effective opportunity to guide, validate, recognize and scale efforts to manage critical health and safety issues in shared spaces. The WELL Health-Safety Rating examines 22 features across five core areas – Cleaning and Sanitization Procedures, Emergency Preparedness Programs, Health Service Resources, Air and Water Quality Management, and Stakeholder Engagement and Communication – and requires a minimum of 15 criteria be met in order to achieve the rating and be awarded the WELL Health-Safety seal.

As such, the seal is a symbol of trust and confidence that is backed by science, structure and, most importantly, third-party verification. IWBI has seen thousands of buildings enroll in the program since its launch in July 2020, and expects significant global adoption to continue in 2021 and beyond.

“While the WELL Health-Safety Rating was a response to this moment in time, it was developed to address broader health and safety-related issues well into the future,” said Rachel Hodgdon, President and CEO of the International WELL Building Institute. “We collaborated with our global community to create something that’s flexible for all building types and organizational priorities. This consistency across market sectors means people will see the seal at their favorite restaurants, stadiums and hotels, and at their office, childcare center or college campus and know it stands for the same thing in every location, that science-based strategies have been implemented and safety has been prioritized.”

The WELL Health-Safety Rating was developed in response to market demand and informed by IWBI’s Task Force on COVID-19, which included nearly 600 public health experts, virologists, government officials, academics, business leaders, architects, designers, building scientists and real estate professionals. More than 1.5 billion square feet of space are enrolled in WELL offerings. To date, Yankee Stadium, the Empire State Building, JPMorgan Chase, RocketMortgage Field House, Amalie Arena, Spectrum Center, Simon Property Group, BB&T Center, Aimbridge Hospitality and AT&T Stadium, among others, have achieved the WELL Health-Safety Rating.

The public awareness campaign launched today and comes to life through TV, digital video and social advertising. TV commercials will appear nationally through early spring 2021. The campaign creative was developed by advertising agency SWAT by Kirshenbaum, directed by Spike Lee and produced by Pony Show Entertainment.

“From an enterprise standpoint, this is an exceptionally exciting time for all of us,” said Delos CMO Anthony Antolino. “Helping everyone to get back to business with confidence is critical, and these celebrity ambassadors are key in helping spread the word.”

For more information about the campaign, please visit www.WellHealthSafety.com.

About the International WELL Building Institute
The International WELL Building Institute (IWBI) is a public benefit corporation and the world’s leading organization focused on deploying people first places to advance a global culture of health. The WELL Building Standard anchors a WELL ecosystem that includes WELL v2, the WELL Community Standard, the WELL Health-Safety Rating and WELL Accredited Professionals. IWBI mobilizes its community through the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and well-being for everyone, everywhere. More information on WELL can be found here.

International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Workforce, WELL Health-Safety Rating, WE ARE WELL, WELL and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Samantha Wolf
Tel. 646-935-4032
samantha.wolf@ketchum.com

Jamie Matos
media@wellcertified.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 13:00:00 EEST | Press release

Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat

Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 12:11:00 EEST | Press release

Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/en/ Haleon Health Ambassador on motorbike, equipped with testing kits, samples and diagnostic tools Building capacity to meet rising demand The new site, which is well-positioned in the middle of the country and close to some of India’s most renowned technical colleges, marks an important step in the delivery of Haleon’s Win as One strategy. Win as On

Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 11:56:00 EEST | Press release

Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the intestinal wall, a fundamentally new pharmacological finding. No nausea or side effects observed: No adverse events observed across the 8-subject cohort over one week, cons

Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 11:00:00 EEST | Press release

Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a

Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 11:00:00 EEST | Press release

Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye